{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:24:42Z","timestamp":1793363082933,"version":"4.5.0"},"reference-count":57,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Taiho Pharma Canada, Inc.","award":["22-0007"],"award-info":[{"award-number":["22-0007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine\/cedazuridine (DEC-C, ASTX727) is Canada\u2019s first and only approved oral hypomethylating agent for MDS and CMML. We characterized the real-world use of DEC-C through a Canadian compassionate use program. Demographic and clinical data from 769 patients enrolled in Taiho Pharma Canada\u2019s Patient Support Program were collected and analyzed. These patients represent a collection period from 10 November 2020 to 31 August 2022 with a median age of 76 years. Among 651 patients who started DEC-C, the median treatment duration was 4.2 cycles. The median overall and progression-free survival were 21.6 and 10.7 months, respectively. Among 427 patients who discontinued treatment, the majority (69.5%) stopped due to death (n = 164) or disease progression (n = 133). Multivariable cox regression showed that age, province of residence, blast counts, antibiotic prophylaxis, and number of dose reductions and delays were not significantly associated with overall and progression-free survival. DEC-C is a promising alternative to parenteral hypomethylating agent therapy, and it likely addresses an important unmet need for effective and convenient therapies in this setting.<\/jats:p>","DOI":"10.3390\/curroncol30090581","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T10:33:56Z","timestamp":1693391636000},"page":"8005-8018","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Decitabine\/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada"],"prefix":"10.3390","volume":"30","author":[{"given":"John Paul","family":"Yun","sequence":"first","affiliation":[{"name":"Oncology Outcomes Program, Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Galway University Hospital, H91 YR71 Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0413-5485","authenticated-orcid":false,"given":"Philip Q.","family":"Ding","sequence":"additional","affiliation":[{"name":"Oncology Outcomes Program, Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aastha","family":"Dolley","sequence":"additional","affiliation":[{"name":"Taiho Pharma Canada, Inc., Oakville, ON L6H 5R7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Oncology Outcomes Program, Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-018-0085-4","article-title":"Myelodysplastic syndromes current treatment algorithm 2018","volume":"8","author":"Steensma","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.25684","article-title":"Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management","volume":"95","author":"Patnaik","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1373\/jalm.2018.026500","article-title":"Incidence of Myelodysplastic Syndromes in a Major Canadian Metropolitan Area","volume":"3","author":"Slack","year":"2018","journal-title":"J. Appl. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"AB130","DOI":"10.1016\/j.jaad.2018.05.543","article-title":"Epidemiology and geographic trends for chronic myelomonocytic leukemia in Canada","volume":"79","author":"Le","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11899-015-0269-y","article-title":"Incidence and Burden of the Myelodysplastic Syndromes","volume":"10","author":"Cogle","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and Treatment of Myelodysplastic Syndromes: A Review","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kasprzak, A., Nachtkamp, K., Gattermann, N., and Germing, U. (2022). Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS). Cancers, 14.","DOI":"10.3390\/cancers14081941"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40164-022-00328-4","article-title":"IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons\u2009\u2265\u200960 years with myelodysplastic syndromes","volume":"11","author":"Wu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Palacios-Berraquero, M.L., and Alfonso-Pi\u00e9rola, A. (2021). Current Therapy of the Patients with MDS: Walking towards Personalized Therapy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10102107"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/cncr.21860","article-title":"Transfusion independence in patients with myelodysplastic syndromes: Impact on outcomes and quality of life","volume":"106","author":"Balducci","year":"2006","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bjh.13450","article-title":"Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: A report from the prospective European LeukaemiaNet MDS (EUMDS) registry","volume":"170","author":"Smith","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Fenaux","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: Recommendations from an international expert panel","volume":"129","author":"Bowen","year":"2017","journal-title":"Blood"},{"key":"ref_17","unstructured":"(2019). DACOGEN (Decitabine) for Injection [Product Monograph], Otsuka Canada Pharmaceutical Inc."},{"key":"ref_18","unstructured":"(2019). DEMYLOCAN (Decitabine) for Injection [Product Monograph], PENDOPHARM, Division of Pharmascience Inc."},{"key":"ref_19","unstructured":"(2018). VIDAZA (Azacitidine) for Injection [Product Monograph], Celgene Inc."},{"key":"ref_20","unstructured":"(2017). Reddy-Azacitidine (Azacitidine) for Injection [Product Monograph], Dr. Reddy\u2019s Laboratories Limited."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1016\/j.clml.2022.04.023","article-title":"Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_22","unstructured":"Buckstein, R., Baldassarre, F., Maze, D., Schuh, A., Cheung, M., and the Myelodysplastic Syndrome Guideline Development Group (2018). Systemic Therapy for the Treatment of Adult Patients with Low-Risk Myelodysplastic Syndromes, Cancer Care Ontario. Program in Evidence-Based Care Guideline No.: 6\u201313."},{"key":"ref_23","unstructured":"(2022). INQOVI (Decitabine and Cedazuridine) Tablets [Product Monograph], Taiho Pharma Canada, Inc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","article-title":"An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: A multicentre, open-label, dose-escalation, phase 1 study","volume":"6","author":"Savona","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: A phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Griffiths","year":"2020","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2019-122980","article-title":"Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine\/decitabine) Compared to IV Decitabine","volume":"134","author":"McCloskey","year":"2019","journal-title":"Blood"},{"key":"ref_27","unstructured":"RStudio Team (2023, June 08). RStudio: Integrated Development for R. RStudio, PBC, Boston, MA URL. Available online: http:\/\/www.rstudio.com\/."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.amjmed.2012.04.014","article-title":"Epidemiology of myelodysplastic syndromes","volume":"125","author":"Ma","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.6004\/jnccn.2011.0006","article-title":"Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010","volume":"9","author":"Sekeres","year":"2011","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_30","unstructured":"Astex Pharmaceuticals (2021). Astex Pharmaceuticals Presents Overall Survival Data from ASCERTAIN Phase 3 Study of Oral Hypomethylating Agent INQOVI (Decitabine and Cedazuridine) in MDS and CMML at International Congress on Myelodysplastic Syndromes, Astex Pharmaceuticals. News Release."},{"key":"ref_31","unstructured":"(2023, June 08). Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT03306264."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.2147\/JMDH.S337039","article-title":"The Impact of COVID-19 Pandemic on Blood Transfusion Services: A Perspective from Health Professionals and Donors","volume":"14","author":"Miskeen","year":"2021","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-138969","article-title":"Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic","volume":"136","author":"Feld","year":"2020","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2022-157926","article-title":"Treatment Patterns and Characteristics Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous\/Subcutaneous Hypomethylating Agents in a Real-World Setting","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/jco.2008.26.15_suppl.7006","article-title":"Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission","volume":"26","author":"List","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"79414","DOI":"10.18632\/oncotarget.18258","article-title":"Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome: A retrospective study from The Korean Society of Hematology AML\/MDS Working Party","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1002\/cncr.25774","article-title":"Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes","volume":"117","author":"Silverman","year":"2011","journal-title":"Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2217\/fon-2021-0936","article-title":"Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: Why are we not achieving the promise of clinical trials?","volume":"17","author":"Zeidan","year":"2021","journal-title":"Future Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/2040620712464882","article-title":"Azacitidine in the management of patients with myelodysplastic syndromes","volume":"3","author":"Khan","year":"2012","journal-title":"Ther. Adv. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2019-128949","article-title":"Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents","volume":"134","author":"Wan","year":"2019","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2010.31.0854","article-title":"Hypomethylating agents and other novel strategies in myelodysplastic syndromes","volume":"29","author":"Fenaux","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/Cedazuridine: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00520-014-2502-y","article-title":"Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders","volume":"23","author":"Tendas","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/hematology.2020000103","article-title":"Outpatient transfusions for myelodysplastic syndromes","volume":"2020","author":"Wood","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11120","DOI":"10.18632\/aging.202767","article-title":"High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: A meta-analysis of prospective studies","volume":"13","author":"Wan","year":"2021","journal-title":"Aging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428194.2018.1464155","article-title":"Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care","volume":"60","author":"Bell","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cam4.1231","article-title":"Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen","volume":"6","author":"Ali","year":"2017","journal-title":"Cancer Med."},{"key":"ref_53","first-page":"5","article-title":"Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents","volume":"89","author":"Livio","year":"2018","journal-title":"Acta Biomed."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1080\/10428194.2019.1703970","article-title":"Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): A large propensity score-matched population-based study\u2020","volume":"61","author":"Davidoff","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/jnci\/djn349","article-title":"Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys","volume":"100","author":"Sekeres","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/cncr.28631","article-title":"Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes","volume":"120","author":"Steensma","year":"2014","journal-title":"Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e019955","DOI":"10.1136\/bmjopen-2017-019955","article-title":"Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States","volume":"8","author":"Ma","year":"2018","journal-title":"BMJ Open"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/581\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:42:43Z","timestamp":1760128963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/9\/581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["curroncol30090581"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30090581","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]}}}